Rosenburg R - Search Results

1

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R. Smolen JS, et al. Among authors: rosenburg r. Lancet. 1999 Jan 23;353(9149):259-66. doi: 10.1016/s0140-6736(98)09403-3. Lancet. 1999. PMID: 9929017 Clinical Trial.

2

Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.

Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R; European Leflunomide Study Group. Kalden JR, et al. Among authors: rosenburg r. J Rheumatol. 2001 Sep;28(9):1983-91. J Rheumatol. 2001. PMID: 11550964 Clinical Trial.

3

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, Van Den Bosch F, Nordström D, Bjorneboe O, Dahl R, Horslev-Petersen K, Rodriguez De La Serna A, Molloy M, Tikly M, Oed C, Rosenburg R, Loew-Friedrich I. Emery P, et al. Among authors: rosenburg r. Rheumatology (Oxford). 2000 Jun;39(6):655-65. doi: 10.1093/rheumatology/39.6.655. Rheumatology (Oxford). 2000. PMID: 10888712 Clinical Trial.

4

Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine.

Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, Rozman B, Westhovens R, Tikly M, Oed C, Rosenburg R; European Leflunomide Study Group. Larsen A, et al. Among authors: rosenburg r. Scand J Rheumatol. 2001;30(3):135-42. doi: 10.1080/030097401300162897. Scand J Rheumatol. 2001. PMID: 11469522 Clinical Trial.

5

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.

Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP. Kraan MC, et al. Among authors: rosenburg r. Arthritis Rheum. 2000 Aug;43(8):1820-30. doi: 10.1002/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D. Arthritis Rheum. 2000. PMID: 10943872 Free article. Clinical Trial.

6

First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18.

Finkel JC, Goldberg J, Rosenburg R, Ariyawansa J, Sun T, Ochs-Ross R, Zannikos P, Zhang L, Etropolski M. Finkel JC, et al. Among authors: rosenburg r. J Pain Res. 2019 Jun 28;12:1925-1936. doi: 10.2147/JPR.S197348. eCollection 2019. J Pain Res. 2019. PMID: 31303784 Free PMC article.

7

Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients.

Muse D, Tarau E, Lefeber C, Sohns M, Brett M, Goldberg J, Rosenburg R. Muse D, et al. Among authors: rosenburg r. J Pain Res. 2019 May 31;12:1777-1790. doi: 10.2147/JPR.S197039. eCollection 2019. J Pain Res. 2019. PMID: 31213888 Free PMC article.

8

Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid.

Hinder M, Frick A, Rosenburg R, Hesse G, Ozoux ML, Laux V, Scholtz H, Gebauer A, Paccaly A. Hinder M, et al. Among authors: rosenburg r. Thromb Haemost. 2006 Feb;95(2):224-8. doi: 10.1160/TH05-08-0592. Thromb Haemost. 2006. PMID: 16493482 Clinical Trial.

9

Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects.

Paccaly A, Frick A, Ozoux ML, Chu V, Rosenburg R, Hinder M, Shukla U, Jensen BK. Paccaly A, et al. Among authors: rosenburg r. J Clin Pharmacol. 2006 Jan;46(1):45-51. doi: 10.1177/0091270005281818. J Clin Pharmacol. 2006. PMID: 16397283 Clinical Trial.

10

Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure.

Paccaly A, Frick A, Rohatagi S, Liu J, Shukla U, Rosenburg R, Hinder M, Jensen BK. Paccaly A, et al. Among authors: rosenburg r. J Clin Pharmacol. 2006 Jan;46(1):37-44. doi: 10.1177/0091270005281817. J Clin Pharmacol. 2006. PMID: 16397282 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page